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Abstract Leptin, a fat secreted hormone, regulates ingestive
behaviour and energy balance by binding to a specific receptor.
Using site-directed mutagenesis, we screened for single amino
acid residues in human leptin which are critical for receptor
binding and biological activity. Here we report that one of these
mutants has in vivo antagonistic properties. An Arg to Gln
substitution at position 128 of human leptin does not affect
receptor binding but knocks out biological activity. Repeated
injection of R128Q in normal C57BL/6J mice results in a
progressive increase in body weight. This demonstrates that
R128Q is able to interfere with the negative feedback control of
endogenous leptin. This mutant could be of therapeutic use for
wasting disorders, such as anorexia and cachexia, where weight
gain would be beneficial.
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1. Introduction
Leptin, the product of the ob gene, plays a central role in
the control of body adiposity. Genetic defects that lead to
leptin de¢ciency (ob/ob mice) or leptin resistance (db/db
mice, fa/fa rats) both cause severe obesity [1^3]. Administra-
tion of recombinant leptin decreases food intake and increases
energy expenditure in ob/ob mice and WT mice [4^6]. The
weight reducing e¡ects are likely mediated through a signaling
leptin receptor in the hypothalamus [7,8]. Leptin itself displays
no apparent sequence similarity to any other existing protein.
Yet structure prediction and comparison algorithms unmis-
takably identify leptin as a member of the haemopoietic cy-
tokine family that adopt a four K-helix bundle fold [9,10].
This observation is further corroborated by the identi¢cation
of a leptin receptor that resembles other haemopoietic-class
receptors such as the IL-6 signal transducing chain, gp 130 [7].
In order to investigate the interaction with its receptor we
constructed a series of point mutations in human leptin. Mu-
tant proteins were tested for binding and in vitro biological
activity. In the present report we show that one mutant,
R20Q, a¡ects receptor binding. Three other mutants, D40N,
S127D and R128Q, although they bind normally to the mouse
leptin receptor, show reduced biological activity. One of these,
R128Q, is unable to trigger intracellular signaling. As such,
R128Q has the characteristics of a competitive inhibitor. In
order to investigate antagonistic properties of R128Q in vivo,
we treated lean C57BL/6 mice with this mutant. Here we show
that R128Q induces an obese phenotype in these animals and
increases serum insulin levels, features reminiscent of leptin-
de¢cient mice.
2. Materials and methods
2.1. Mutagenesis
Human leptin cDNA was subcloned into the pSV-SPORT1 vector
(BRL-Gibco) and site-directed mutagenesis was carried out according
to the method of Deng and Nickolo¡ [11] with a Transformer kit
(Clontech). Mutant proteins were expressed in COS1 cells as described
(DEAE dextran method [12]). R20Q, D40N, S127D and R128Q were
also subcloned in the pVL1393 vector for expression in Sf9 insect cells
(Baculogold, Pharmingen) and puri¢ed by immunoa¤nity chromatog-
raphy using a mAb (2A5) directed against human leptin.
2.2. Competition binding assay.
COS1 cells were transfected with murine leptin receptor cDNA [7].
2U10
5
cells were incubated in 200 Wl Dulbecco's modi¢ed Eagle's
medium (DMEM) supplemented with 10% FCS for 3^5 h at 4³C
with 1 nM
125
I-labelled human leptin in combination with increasing
concentrations of unlabelled leptin or leptin mutants. Bound ligand
was separated from free radioactivity by centrifugation through a
phthalate oil cushion and Q emission was counted.
2.3. BAF3 1423 proliferation assay
A chimeric leptin receptor construct was made by fusing the extra-
cellular and transmembrane domain of the murine leptin receptor [7]
with the intracellular domain of the human L
c
receptor (L
c
is a com-
mon receptor subunit present in the IL-3, IL-5 and GM-CSF receptor
complex [13]). The DNA fragments were linked by PCR generated
BamHI sites. IL-3- or GM-CSF-dependent BAF3 cells were trans-
fected with this construct as described [14] and responsive cells were
selected in leptin-containing growth medium. One of several inde-
pendent clones, BAF3 1423, was used to set up a leptin proliferation
bioassay. Overnight-starved BAF3 1423 cells were incubated at
1U10
3
cells/200 Wl in 96-well microtiter plates with variable concen-
trations of wild-type leptin or leptin-mutein. After 72 h, 0.5 WCi
[
3
H]thymidine was added for 4 h and the cells were harvested. The
incorporated label was counted with a Topcount scintillation counter
(Packard, Canberra).
2.4. Injections into ob/ob mice
8^10-week-old ob/ob mice were treated for 9 days with human lep-
tin, S127D, R128Q or PBS (control). Injections were given i.p. daily at
5.30 p.m.
15 Wg leptin or mutant in combination with 1.8 mg 2A5 was given
per animal per day. Body weight was monitored by weighing the
animals at 5.00 p.m.
2.5. Injections into C57BL/6J mice
Nine 9^10-week-old C57BL/6J mice were injected twice daily (9.30
a.m. and 5.30 p.m.) with human leptin (100 Wg/injection), R128Q (100
Wg/injection) or PBS (control) in presence of 1.38 mg 2A5 per injec-
tion. Mice were weighed daily at 9.00 a.m.
2.6. Insulin determination
Serum insulin levels were determined using a commercially available
RIA (Linco Research).
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3. Results and discussion
To study the interaction of leptin with its receptor we gen-
erated 37 human leptin mutants, among which 29 resulted
from changing a charged to an uncharged amino acid residue.
Muteins were expressed in COS1 and baculovirus-infected in-
sect cells, and the expression level in the supernatant was
quanti¢ed by an ELISA using mouse mAbs and polyclonal
rabbit IgG directed against human leptin (data not shown).
All muteins were tested in a competition binding experiment
by measuring displacement of
125
I-labelled human leptin from
the murine leptin receptor expressed on COS1 cells. The bio-
logical activity was evaluated in an in vitro assay based on
proliferation of leptin-sensitive BAF3 1423 cells. These cells
were obtained after transfection of BAF3 cells with a plasmid
encoding a chimeric receptor consisting of the mouse leptin
receptor extracellular domain fused to the cytoplasmic do-
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Fig. 1. Analysis of receptor binding and in vitro biological activity
of di¡erent human leptin mutants. A:
125
I-labelled human leptin dis-
placement by cold wild-type leptin (WT) or leptin muteins, on
COS1 cells transiently transfected with the murine leptin receptor.
Each point represents meanþS.E.M. cpm bound
125
I-labelled leptin
(n=3). The binding a¤nity of the mutants D40N, S127D and
R128Q for the receptor was indistinguishable from that of wild-type
leptin (K
d
: þ 1 nM). B: Activities of wild-type leptin and leptin mu-
teins, in the BAF3 1423 proliferation assay. Data are expressed as
meanþS.E.M. cpm incorporated [
3
H]thymidine (n=3). 1 ng/ml lep-
tin induces 50% of maximal proliferation. D40N has 30-fold less ac-
tivity than wild type. S127D has only marginal and R128Q no pro-
liferative activity at all.
Fig. 2. In vivo biological e¡ects of mutants and wild-type leptin. A:
E¡ect on body weight in ob/ob mice. Control group was injected
with PBS. Data expressed in the ¢gure are mean weight changeþ
S.E.M. (n=3). Initial body weight of each treated group was for
wild type: 39.4þ 2.2 g, S127D: 40.6þ 1.2 g, R128Q: 41.0þ 2.9 g
and control: 41.5þ 4.2 g. B: E¡ect on body weight in lean C57BL/
6J mice. Mice were injected twice daily with relatively high amounts
(100 Wg/injection) of R128Q, wild-type leptin or control. Data in the
¢gure display mean change of body weight per groupþS.E.M.
(n=3). Initial body weight for each group was: wild type: 21.6þ 0.6
g, R128Q: 21.5þ 0.9 g and control: 21.0þ 1.0 g. C: Serum insulin
levels of C57BL/6J mice after 15 days of treatment with R128Q,
wild-type leptin or PBS (control). Two serum samples per mouse
were tested and the data represent mean insulin concentration
(n=6) of each group.
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main of the human common L receptor. Most of the mutants
showed similar binding and biological activity as wild type
(data not shown). R20Q was unable to bind to the receptor
(Fig. 1A). As expected, this mutant was also inactive in the
proliferation assay (Fig. 1B). Interestingly three single point
mutations, D40N, S127D and R128Q, did not a¡ect receptor
binding (Fig. 1A) but had profound e¡ects on biological ac-
tivity. Although normal receptor binding was observed, D40N
showed reduced and S127D a very weak proliferative res-
ponse, while R128Q had no biological activity at all (Fig.
1B). BAF3 1423, in contrast to untransfected cells, exhibited
some growth factor-independent proliferation probably
through constitutive activation of the chimeric receptor. In-
terestingly, R128Q completely inhibited this background pro-
liferation at concentrations above 10 ng/ml (Fig. 1B). We also
found that S127D and especially R128Q at high doses can
antagonise the proliferative stimulus of wild-type human lep-
tin (data not shown).
Loss of biological activity despite normal receptor binding
suggests that these muteins could prevent receptor oligomer-
isation. Homodimerisation of the extracellular domain of the
leptin receptor is most likely responsible for leptin-mediated
signaling [15,19] and leptin receptor homodimers can be ob-
served after chemical cross-linking (Devos et al., in prepara-
tion). However, no di¡erent cross-linking patterns relative to
wild-type leptin were seen with D40N, S127D and R128Q
(data not shown). Alternatively, the mutated residues might
be crucial for receptor activation by inducing allosteric
changes in the receptor upon binding. Finally it cannot be
excluded that S127, R128 and to a lesser extend D40 are
involved in binding of an as yet unidenti¢ed leptin receptor
accessory chain.
Treatment of obese C57BL/6J (ob/ob) mice with exogenous
recombinant leptin decreases food intake, increases energy
expenditure and decreases plasma insulin levels [4^6]. This
results in a net reduction of body weight. We have previously
observed that co-administration of human leptin with a
monoclonal antibody (2A5) directed against human leptin en-
hances the leptin e¡ect (Van der Heyden et al., in prepara-
tion). The mechanism of this potentiation is unclear at
present. The antibody could increase the half-life of leptin in
serum, alternatively it might a¡ect tissue distribution or trans-
port to the brain. The biological activity of the muteins
S127D and R128Q was tested in ob/ob mice by i.p. adminis-
tration together with 2A5 (Fig. 2A). As expected, treatment
with wild-type human leptin led to signi¢cant weight loss (up
to 1 g day
31
), while no e¡ect was observed in animals injected
with S127D and R128Q. Taken together, the injections into
ob/ob mice unambiguously demonstrate the lack of biological
activity of S127D and R128Q, which is in accordance with the
inability of these muteins to trigger a proliferative response in
BAF3 1423 cells.
Since R128Q can compete with leptin for receptor binding
it is conceivable that, at a high dose, it should be able to block
the activity of resident leptin in vivo. To test this hypothesis
lean C57BL/6J mice were i.p. injected twice a day with 100 Wg
R128Q. Control groups were treated with an equal dose of
wild-type leptin or carrier without leptin. To potentiate the
activity of leptin or the mutant, 2A5 mAb was co-injected. As
can be seen from Fig. 2B, animals treated for 15 days with
R128Q gradually gained about 25% of their initial body
weight. We observed a signi¢cant increase in white fat depos-
its in these animals (not shown). In contrast, animals that
were injected with wild-type leptin rapidly lost circa 15% of
their initial body weight and maintained this plateau as long
as the injections lasted. When the treatment was stopped both
the R128Q- and the wild-type leptin-treated animals returned
to control body weight levels (not shown). We also measured
serum insulin levels after 15-day treatment (Fig. 2C). Insulin
concentrations of R128Q-injected mice were signi¢cantly in-
creased relative to controls. Treatment with wild-type leptin
showed an opposite e¡ect. From these observations it can be
concluded that R128Q behaves as a potent antagonist of the
endogenous mouse leptin.
Several compounds with appetite- and weight-enhancing
e¡ects have been developed and are being investigated for
potential use in patients with anorexia and cachexia [16]. Re-
cently a role for leptin in anorexia caused by infection was
suggested. Endotoxin and in£ammatory cytokines such as
TNF and IL-1, which mediate anorexia, have been shown
to induce leptin expression [17,18]. Further study is warranted
to investigate if R128Q could restore body weight in animal
models of anorexia and cachexia. In this context, a leptin
mutein with in vivo antagonistic e¡ects could be therapeuti-
cally useful to prevent weight loss during chronic diseases,
such as anorexia nervosa, cancer and AIDS.
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